OBJECTIVES: To investigate real-world treatment outcomes experienced by people with HIV (PWH) who are switched to B/F/TAF or other antiretroviral (ARV) regimens in the United States (US).

METHODS: Data were drawn from the Adelphi HIV Disease Specific Programme™, a real-world, cross-sectional survey from physicians and PWH in the US from July 2021 to March 2022. Physicians provided data for PWH, including demographics, clinical characteristics, and adherence. Comparisons were made using Fisher’s exact and t-tests.

RESULTS: Physicians (n=60) provided data on 236 treatment-experienced PWH. PWH who had switched to B/F/TAF (n=89) were compared to those who switched to other ARV regimens (n=147). Mean time [SD] from diagnosis was 12.4 [9.2] years (B/F/TAF: 9.3 [8.6]; ARVs: 10.3 [9.5]); PWH had received a mean of 2.7 [1.2] ARV regimens (B/F/TAF: 2.6 [1.1]; ARVs: 2.8 [1.3]). Physician assessment of PWH adherence to current regimen was high (completely/mostly adherent; B/F/TAF: 96.7%; ARVs: 93.9%; p>0.05). Over half of PWH had no current adverse events (B/F/TAF: 61.8%; ARVs: 58.5%), with weight gain being more common in PWH switched to other ARVs (B/F/TAF: 4.5%; ARVs: 13.6%; p<0.05). Reasons for switch from previous regimen included physician decision (B/F/TAF: 36.0%; ARVs: 25.2%) and adverse events from previous regimen (B/F/TAF: 16.3%; ARVs: 18.7%). Compared to B/F/TAF switch, PWH who switched to other ARV regimens had more laboratory monitoring tests for HIV over the 12 months after switching (B/F/TAF:17.6; ARVs: 22.5; p<0.05).

CONCLUSIONS: Switch of ARVs in treatment-experienced PWH was primarily due to physician decision. More research is needed to investigate physician switch decisions. PWH switching to B/F/TAF experienced less weight gain as well as less laboratory monitoring compared to switching to non-B/F/TAF regimens.